Read by QxMD icon Read

Rheuma club

shared collection
6 papers 0 to 25 followers
Daniel Wendling, Clément Prati
No abstract text is available yet for this article.
June 2016: Annals of the Rheumatic Diseases
Alessandro Battaggia, Pierangelo Lora Aprile, Iacopo Cricelli, Diego Fornasari, Andrea Fanelli, Claudio Cricelli, Francesco Lapi
No abstract text is available yet for this article.
September 2016: Annals of the Rheumatic Diseases
Shaye Kivity, Yaron Zafrir, Ronen Loebstein, Rachel Pauzner, Meir Mouallem, Haim Mayan
OBJECTIVE: Low dose (10-25 mg/week) methotrexate is widely used for the management of systemic inflammatory diseases, and is considered to be relatively safe. Toxicity due to low dose MTX has been reported but is poorly characterized. We describe the clinical features, risk factors, and outcomes of low dose MTX toxicity in a large case series at our center. PATIENTS AND METHODS: We conducted a retrospective case series of all adult (>18 years) patients hospitalized at Sheba Medical Center, between 2005 and 2012 for low dose MTX toxicity...
November 2014: Autoimmunity Reviews
Sergey Moiseev, Pavel Novikov, Victor Fomin
No abstract text is available yet for this article.
August 2016: Annals of the Rheumatic Diseases
Hugh J Willison, Bart C Jacobs, Pieter A van Doorn
Guillain-Barré syndrome is the most common and most severe acute paralytic neuropathy, with about 100,000 people developing the disorder every year worldwide. Under the umbrella term of Guillain-Barré syndrome are several recognisable variants with distinct clinical and pathological features. The severe, generalised manifestation of Guillain-Barré syndrome with respiratory failure affects 20-30% of cases. Treatment with intravenous immunoglobulin or plasma exchange is the optimal management approach, alongside supportive care...
August 13, 2016: Lancet
Sofia Ramiro, Josef S Smolen, Robert Landewé, Désirée van der Heijde, Maxime Dougados, Paul Emery, Maarten de Wit, Maurizio Cutolo, Susan Oliver, Laure Gossec
OBJECTIVE: To update the evidence on the efficacy and safety of pharmacological agents in psoriatic arthritis (PsA). METHODS: Systematic literature review of randomised controlled trials comparing pharmacological interventions in PsA: non-steroidal anti-inflammatory drugs, glucocorticoid, synthetic disease modifying antirheumatic drugs (sDMARDs) either conventional or targeted, biologicals (bDMARDs), placebo or any combination. Main outcomes were American College of Rheumatology (ACR)20-50, Psoriasis Area Severity Index 75, radiographic progression, and withdrawals due to adverse events (AEs)...
March 2016: Annals of the Rheumatic Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"